Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

In the News
Greg Scott presents industry update during JPMorgan
>> View video…

>> More News...

Now on Twitter!
 

Twitter ID: ChinaBio

NovaMed Buys China Rights for Cancer Pain Drug from Orexo

publication date: Jan 27, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

NovaMed Pharmaceuticals has signed a $5 million licensing and distribution agreement with Orexo that gives NovaMed the right to seek approval in China for Abstral, Orexo´s drug for breakthrough cancer pain. If the drug is approved, NovaMed will distribute Orexo in China. The agreement calls for an upfront payment, regulatory milestones and sales milestones. NovaMed will be responsible for the regulatory approval process including the necessary clinical studies. More details...

Stock Symbols: (STO: ORX) (NYSE: PFE)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
ChinaBio® Events
April 14, 2010
Guangzhou, China

SEED Final Competion and Award Ceremony
April 23, 2010
Shanghai, China
Suzhou, China
June 23-24, 2010
 
Partner Events

China 2010 Pharmaceutical R&D Summit
Shanghai, China
April 5-8, 2010

Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners